Iodixanol

Drug Profile

Iodixanol

Alternative Names: 2 5410 3A; DU 6807; Visipaque

Latest Information Update: 08 Apr 2014

Price : $50

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare
  • Class Contrast media; Triiodobenzoic acids
  • Mechanism of Action Radiography enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 31 Mar 2014 Final adverse events data from a head-to-head phase IV trial in Cardiovascular disorders (diagnosis) presented at the 63rd Annual Scientific Session of the American College of Cardiology (ACC-2014) .
  • 05 Mar 2014 Final efficacy data from a head to head study in Cardiovascular disorders (diagnosis) released by GE Healthcare
  • 29 Oct 2013 GE Healthcare plans a large phase IV safety trial for Cardiovascular disorders (diagnosis) in China (ChiCTR-ONC13003733)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top